Fair Value Measurements, Part 2 (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Total realized/unrealized gains (losses)
Total amount of unrealized gains (losses) for the period included in other comprehensive loss attributable to the change in fair market value of related assets still held at the reporting date	$ 68	$ 8	$ 24
Azedra commercialization [Member]
Fair Value Measurements, Quantitative Information
Period of milestone expected achievement	2017
Fair Value	2,300
Valuation technique	Probability adjusted discounted cash flow model
Discount Rate	10.00%
Probability of success	40.00%
Small molecule therapeutics commercialization [Member]
Fair Value Measurements, Quantitative Information
Period of milestone expected achievement	2021
Fair Value	500
Valuation technique	Probability adjusted discounted cash flow model
Discount Rate	10.00%
Probability of success	19.00%
Net sales targets [Member]
Fair Value Measurements, Quantitative Information
Fair Value	10,900
Valuation technique	Monte-Carlo simulation
Discount Rate	12.50%
Contingent Consideration Liability [Member]
Summary of activities in financial instruments with significant Level 3 inputs [Roll Forward]
Balance at beginning of period	0	0
Total realized/unrealized gains (losses)
Fair value of contingent consideration - acquisition of Molecular Insight	15,900	0
Fair value adjustment to contingent consideration included in net loss	(200)	0
Balance at end of period	15,700	0
Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for assets or liabilities held at the end of the reporting period	(200)	0
MIP - 1404 commercialization [Member]
Fair Value Measurements, Quantitative Information
Period of milestone expected achievement	2018
Fair Value	2,000
Valuation technique	Probability adjusted discounted cash flow model
Discount Rate	10.00%
Probability of success	31.00%
Auction Rate Securities [Member]
Summary of activities in financial instruments with significant Level 3 inputs [Roll Forward]
Balance at beginning of period	3,240	3,332
Transfers into Level 3	0	0
Total realized/unrealized gains (losses)
Included in net income (loss)	0	0
Included in comprehensive income (loss)	68	8
Settlements	(1,100)	(100)
Balance at end of period	2,208	3,240
Total amount of unrealized gains (losses) for the period included in other comprehensive loss attributable to the change in fair market value of related assets still held at the reporting date	0	0
Fair Value Measurements, Quantitative Information
Fair Value	$ 2,208	$ 3,240
Valuation technique	Discounted cash flow model	Discounted cash flow model
Minimum [Member] | Net sales targets [Member]
Fair Value Measurements, Quantitative Information
Period of milestone expected achievement	2018
Probability of success	19.00%
Minimum [Member] | Auction Rate Securities [Member]
Fair Value Measurements, Quantitative Information
Redemption period	5 years	4 years
Discount Rate	0.25%	0.125%
Maximum [Member] | Net sales targets [Member]
Fair Value Measurements, Quantitative Information
Period of milestone expected achievement	2022
Probability of success	40.00%
Maximum [Member] | Auction Rate Securities [Member]
Fair Value Measurements, Quantitative Information
Redemption period	15 years	15 years
Discount Rate	3.00%	2.102%
Weighted average [Member] | Net sales targets [Member]
Fair Value Measurements, Quantitative Information
Probability of success	32.80%
Weighted average [Member] | Auction Rate Securities [Member]
Fair Value Measurements, Quantitative Information
Redemption period	6 years	5 years 10 months 24 days
Discount Rate	1.55%	0.71%